Table 3.
Changes in treatment group from starting treatment for patients treated with monotherapy or combination therapy
| Starting treatment groupa | New treatment group | Percentage switched n (%) |
Median (days)b | IQR |
|---|---|---|---|---|
| Topical, n = 44,603 | Phototherapy | 1613 (3.6) | 48.0 | 0.0–296.0 |
| Oral Systemic | 2232 (5.0) | 139.0 | 14.0–327.3 | |
| Biologic | 2841 (6.4) | 135.0 | 15.0–283.0 | |
| Oral Systemic + Biologic | 9 (0.0) | 30.0 | 0.0–48.0 | |
| Multiple Switch | 11,927 (26.7) | 79.0 | 7.0–243.0 | |
| No Switch | 25,981 (58.2) | 327.0 | 174.8–365.0 | |
| Phototherapy, n = 5248 | Topical | 2438 (46.5) | 84.0 | 33.0–185.0 |
| Oral Systemic | 19 (0.4) | 113.0 | 53.0–149.0 | |
| Biologic | 18 (0.3) | 79.0 | 44.3–142.5 | |
| Oral Systemic + Phototherapy | 45 (0.9) | 56.0 | 5.0–239.0 | |
| Biologic + Phototherapy | 17 (0.3) | 76.0 | 21.0–189.0 | |
| Other Interventions | 665 (12.7) | 35.0 | 3.0–97.0 | |
| Multiple Switch | 726 (13.8) | 98.0 | 45.0–182.0 | |
| No Switch | 1320 (25.2) | 160.0 | 55.0–350.7 | |
| Oral Systemic, n = 7116 | Topical | 1751 (24.6) | 105.0 | 21.0–219.0 |
| Oral Systemic | 7 (0.1) | 0.0 | 0.0–111.0 | |
| Biologic | 6 (0.1) | 34.5 | 7.0–134.8 | |
| Oral Systemic + Phototherapy | 19 (0.3) | 2.0 | 0.0–166.5 | |
| Oral Systemic + Biologic | 73 (1.0) | 35.0 | 0.0–100.0 | |
| Other Interventions | 445 (6.3) | 33.0 | 0.0–136.0 | |
| Multiple Switch | 2459 (34.6) | 117.0 | 45.0–215.5 | |
| No Switch | 2356 (33.1) | 159.0 | 61.0–299.1 | |
| Biologic, n = 11,767 | Topical | 1857 (15.8) | 191.0 | 83.0–290.2 |
| Oral Systemic | 5 (0.0) | 317.0 | 0.0–342.2 | |
| Biologic | 5 (0.0) | 42.0 | 39.0–87.0 | |
| Biologic + Phototherapy | 15 (0.1) | 7.0 | 0.0–204.9 | |
| Oral Systemic + Biologic | 80 (0.7) | 204.8 | 39.5–302.5 | |
| Other Interventions | 800 (6.8) | 0.0 | 0.0–186.6 | |
| Multiple Switch | 4669 (39.7) | 112.0 | 15.0–227.0 | |
| No Switch | 4336 (36.9) | 238.0 | 139.0–319.8 | |
| Oral Systemic + Phototherapy, n = 146 | Topical | 10 (6.9) | 52.5 | 36.5–141.5 |
| Phototherapy | 10 (6.9) | 165.0 | 146.8–240.6 | |
| Oral Systemic | 14 (9.6) | 88.5 | 31.0–132.8 | |
| Multiple Switch | 99 (67.8) | 90.0 | 40.5–156.0 | |
| No Switch | 13 (8.9) | 54.0 | 20.0–144.0 | |
| Biologic + Phototherapy, n = 65 | Biologic | 9 (12.0) | 91.0 | 28.0–227.0 |
| Multiple Switch | 56 (74.7) | 70.0 | 38.8–148.0 | |
| Oral Systemic + Biologic, n = 350 | Oral Systemic | 18 (5.1) | 81.5 | 3.8–210.5 |
| Biologic | 54 (15.2) | 144.5 | 49.8–227.0 | |
| Multiple Switch | 237 (66.8) | 94.0 | 35.0–189.0 | |
| No Switch | 41 (11.6) | 140.1 | 48.0–298.5 | |
| Oral Systemic + Biologic + Phototherapy, n = 5 | Multiple Switch | 5 (100.0) | 137.0 | 109.0–196.0 |
| Other Interventions, n = 13,200 | Topical | 1782 (13.5) | 25.5 | 0.0–140.0 |
| Phototherapy | 408 (3.1) | 0.0 | 0.0–0.0 | |
| Oral Systemic | 491 (3.7) | 0.0 | 0.0–86.0 | |
| Biologic | 1488 (11.3) | 12.0 | 0.0–158.3 | |
| Multiple Switch | 4835 (36.6) | 13.0 | 0.0–102.5 | |
| No Switch | 4196 (31.8) | 265.0 | 115.9–365.0 |
IQR interquartile range
aPatient numbers provided for starting treatment as documented in EMA for the study period
bFor patients tracked in EMA prior to the study initiation date, their first visit date was captured and time on treatment was normalized to account for overall time documented in EMA